Oxygen saturation targets in neonatal care: A narrative review
Early Human Development · 2024-12 · 199 · 106134
DOI: 10.1016/j.earlhumdev.2024.106134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Early Human Development, 2024-12. Verfasst von Tri C Nguyen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente North California, 1640, Eureka Rd, Roseville, CA 95661, USA. Hauptthemen laut MEDLINE: Oxygen Saturation. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NICHD NIH HHS, National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Optimal oxygenation requires the delivery of oxygen to meet tissue metabolic demands while minimizing hypoxic pulmonary vasoconstriction and oxygen toxicity. Oxygen saturation by pulse oximetry (SpO2) is a continuous, non-invasive method for monitoring oxygenation. The optimal SpO2 target varies during pregnancy and neonatal period. Maternal SpO2 should ideally be ≥95 % to ensure adequate fetal oxygenation. Term neonates can be resuscitated with an initial oxygen concentration of 21 %, while moderately preterm infants require 21-30 %. Extremely preterm infants may need higher FiO2, followed by titration to desired SpO2 targets. During the NICU course, extremely preterm infants managed with an 85-89 % SpO2 target compared to 90-94 % are associated with a reduced incidence of severe retinopathy of prematurity (ROP) requiring treatment, but with higher mortality. During the later stages of ROP progression, studies suggest that higher SpO2 targets may help limit progression. A target SpO2 of 90-95 % is generally reasonable for term infants with respiratory disease or pulmonary hypertension, with few exceptions such as severe acidosis, therapeutic hypothermia, and possibly dark skin pigmentation, where 93-98 % may be preferred. Infants with cyanotic heart disease and single-ventricle physiology have lower SpO2 targets to avoid pulmonary over-circulation. In low- and middle-income countries (LMICs), the scarcity of oxygen blenders and continuous monitoring may pose a challenge, increasing the risks of both hypoxia and hyperoxia, which can lead to mortality and ROP, respectively. Strategies to mitigate hyperoxia among preterm infants in LMICs are urgently needed to reduce the incidence of ROP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kaiser Permanente North California, 1640, Eureka Rd, Roseville, CA 95661, USA.
- Department of Pediatrics, SIGMA Hospital, P8/D, Kamakshi Hospital Road, Mysore 570009, India.
- Department of Pediatrics, UC Davis Children's Hospital, 2516 Stockton Blvd, Sacramento, CA 95817, USA. Electronic address: hsiefkes@ucdavis.edu.
- Department of Pediatrics, UC Davis Children's Hospital, 2516 Stockton Blvd, Sacramento, CA 95817, USA. Electronic address: milim@ucdavis.edu.
- Department of Pediatrics, UC Davis Children's Hospital, 2516 Stockton Blvd, Sacramento, CA 95817, USA. Electronic address: slakshmi@ucdavis.edu.
Förderung
- NCATS NIH HHS
- NICHD NIH HHS
- National Institute of Child Health and Human Development
Zitieren
APA
Nguyen, T. C., Madappa, R., Siefkes, H. M., Lim, M. J., Siddegowda, K. M., & Lakshminrusimha, S. (2024). Oxygen saturation targets in neonatal care: A narrative review. Early Human Development, 199, 106134. https://doi.org/10.1016/j.earlhumdev.2024.106134
Vancouver
Nguyen TC, Madappa R, Siefkes HM, Lim MJ, Siddegowda KM, Lakshminrusimha S. Oxygen saturation targets in neonatal care: A narrative review. Early Human Development. 2024;199:106134. doi:10.1016/j.earlhumdev.2024.106134
BibTeX
@article{Nguyen2024,
author = {Nguyen, Tri C and Madappa, Rajeshwari and Siefkes, Heather M and Lim, Michelle J and Siddegowda, Kanya Mysore and Lakshminrusimha, Satyan},
title = {Oxygen saturation targets in neonatal care: A narrative review},
journal = {Early Human Development},
year = {2024},
volume = {199},
pages = {106134},
doi = {10.1016/j.earlhumdev.2024.106134}
}
EUVIMED